CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 255 enrolled
Drug / intervention
Inflectra +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05375942
NCT05375942N/ACompleted

Characteristics and 6-month Outcomes Among Real-World Rheumatoid Arthritis Patients Initiating Inflectra

Pfizer·observational·Posted May 17, 2022·Updated Apr 12, 2024

In Brief

An observational study evaluating Inflectra for Arthritis, Rheumatoid. Completed, enrolled 255 participants across 1 site.

Detailed Summary

This is a retrospective observational study looking at the characteristics and outcomes of participants taking Inflectra using the CorEvitas Rheumatoid Arthritis Registry.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedMay 17, 2022
Enrollment StartNov 11, 2022
Primary CompletionNov 11, 2022
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 4.1 years ago

Interventions

Inflectradrug

1\. To describe the characteristics of patients newly initiated on Inflectra.

Inflectradrug

2\. To describe 6-month outcomes after initiating Inflectra, among patients who have 6 months follow-up information in the CorEvitas' RA Registry.